Imperial College London
Portrait Picture

Professor Tony Cass

Faculty of Natural Sciences, Department of Chemistry

Senior Research Investigator
 
 
 
//

Contact

 

+44 (0)20 7594 5195t.cass

 
 
//

Location

 

301KMolecular Sciences Research HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rawson:2019:10.1016/s2589-7500(19)30131-1,
author = {Rawson, TM and Gowers, SAN and Freeman, DME and Wilson, RC and Sharma, S and Gilchrist, M and MacGowan, A and Lovering, A and Bayliss, M and Kyriakides, M and Georgiou, P and Cass, AEG and O'Hare, D and Holmes, AH},
doi = {10.1016/s2589-7500(19)30131-1},
journal = {The Lancet Digital Health},
pages = {e335--e343},
title = {Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers},
url = {http://dx.doi.org/10.1016/s2589-7500(19)30131-1},
volume = {1},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Enhanced methods of drug monitoring are required to support the individualisation of antibiotic dosing. We report the first-in-human evaluation of real-time phenoxymethylpenicillin monitoring using a minimally invasive microneedle-based β-lactam biosensor in healthy volunteers.Methods: This first-in-human, proof-of-concept study was done at the National Institute of Health Research/Wellcome Trust Imperial Clinical Research Facility (Imperial College London, London, UK). The study was approved by London-Harrow Regional Ethics Committee. Volunteers were identified through emails sent to a healthy volunteer database from the Imperial College Clinical Research Facility. Volunteers, who had to be older than 18 years, were excluded if they had evidence of active infection, allergies to penicillin, were at high risk of skin infection, or presented with anaemia during screening. Participants wore a solid microneedle β-lactam biosensor for up to 6 h while being dosed at steady state with oral phenoxymethylpenicillin (five 500 mg doses every 6 h). On arrival at the study centre, two microneedle sensors were applied to the participant's forearm. Blood samples (via cannula, at −30, 0, 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 min) and extracellular fluid (ECF; via microdialysis, every 15 min) pharmacokinetic (PK) samples were taken during one dosing interval. Phenoxymethylpenicillin concentration data obtained from the microneedles were calibrated using locally estimated scatter plot smoothing and compared with free-blood and microdialysis (gold standard) data. Phenoxymethylpenicillin PK for each method was evaluated using non-compartmental analysis. Area under the concentration–time curve (AUC), maximum concentration, and time to maximum concentration were compared. Bias and limits of agreement were investigated with Bland–Altman plots. Microneedle biosensor limits of detection were estimated. The study was registered with Clinical
AU  - Rawson,TM
AU  - Gowers,SAN
AU  - Freeman,DME
AU  - Wilson,RC
AU  - Sharma,S
AU  - Gilchrist,M
AU  - MacGowan,A
AU  - Lovering,A
AU  - Bayliss,M
AU  - Kyriakides,M
AU  - Georgiou,P
AU  - Cass,AEG
AU  - O'Hare,D
AU  - Holmes,AH
DO  - 10.1016/s2589-7500(19)30131-1
EP  - 343
PY  - 2019///
SN  - 2589-7500
SP  - 335
TI  - Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers
T2  - The Lancet Digital Health
UR  - http://dx.doi.org/10.1016/s2589-7500(19)30131-1
UR  - https://www.thelancet.com/journals/landig/article/PIIS2589-7500(19)30131-1/fulltext
UR  - http://hdl.handle.net/10044/1/73699
VL  - 1
ER  -
Download